Keyphrases
Hepatitis C
100%
Response Rate
100%
Chronic Hepatitis C
100%
Pegylated Interferon Plus Ribavirin
100%
Non-responders
80%
Retreatment
80%
Sustained Response
60%
Ribavirin
40%
Pregenomic RNA (pgRNA)
40%
Standard of Care
40%
Adverse Events
20%
Therapeutic Strategies
20%
Patient Characteristics
20%
Relapser
20%
Non-response
20%
Maintenance Therapy
20%
Risk-benefit Ratio
20%
Sustained Virological Response
20%
Pegylated Interferon
20%
Ropeginterferon alfa-2b
20%
Nave
20%
Lag behind
20%
Previous Treatment
20%
Extended Treatment
20%
Previously Treated Patients
20%
Pegylated Interferon alfa-2a
20%
Individual Benefits
20%
EPIC Study
20%
Directly Acting Antivirals
20%
Virological Breakthrough
20%
Nursing and Health Professions
Chronic Hepatitis C
100%
Ribavirin
100%
Peginterferon Alpha
100%
Retreatment
80%
Peginterferon
60%
Health Care Quality
40%
Virus RNA
40%
Adverse Event
20%
Antivirus Agent
20%
Maintenance Therapy
20%
Peginterferon Alpha2a
20%
Peginterferon Alpha2b
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis C
100%
Ribavirin
100%
Peginterferon Alpha
100%
Peginterferon
60%
Virus RNA
40%
Adverse Event
20%
Antivirus Agent
20%
Peginterferon Alpha2a
20%
Peginterferon Alpha2b
20%
Neuroscience
Hepatitis C
100%
Peginterferon Alpha
100%
Ribavirin
100%
Pegylated Interferon
60%
Antivirals
20%
Peginterferon Alfa-2b
20%
Peginterferon Alfa-2a
20%